Valuation Compass Therapeutics, Inc. OTC Markets
Stocks
CMPX
US20454B1044
Biotechnology & Medical Research
|
Delayed
OTC Markets
15:59:57 2021-11-03 EDT
|
5-day change | 1st Jan Change | ||
| 3.550 USD | -10.80% |
|
+32.67% | - |
| 09-23 | Compass Therapeutics Shares Drop After Downgrade From Wedbush | MT |
| 09-23 | Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 | MT |
Company Valuation: Compass Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 309 | 633.5 | 198.8 | 199.5 | 955.1 | 154.3 | - | - |
| Change | - | 105.02% | -68.61% | 0.34% | 378.75% | -83.85% | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 72.78 | 955.1 | 4.281 | 21.28 | 38.28 |
| Change | - | 105.02% | -68.61% | -63.39% | 1,212.3% | -99.55% | 397.07% | 79.88% |
| P/E | -2.42x | -13.6x | -4.73x | -4.03x | -12.8x | -1.73x | -1.53x | -1.95x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.4x | -0.44x | -0.8x | -0.1x | -0.1x | 0.1x |
| Capitalization / Revenue | - | - | - | 235x | - | - | 23.7x | 3.44x |
| EV / Revenue | - | - | - | 85.6x | - | - | 3.27x | 0.85x |
| EV / EBITDA | -3.8x | -15.5x | -4x | -1.3x | -13.2x | -0.04x | -0.19x | -0.31x |
| EV / EBIT | -3.77x | -15.2x | -3.95x | -1.29x | -13.1x | -0.04x | -0.19x | -0.37x |
| EV / FCF | -14.3x | - | - | -1.62x | -19.4x | -0.06x | -0.22x | -0.4x |
| FCF Yield | -6.98% | - | - | -61.7% | -5.15% | -1,700% | -450% | -248% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.31 | -0.37 | -0.33 | -0.36 | -0.42 | -0.496 | -0.5586 | -0.44 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 0.85 | - | - | 6.512 | 44.82 |
| EBITDA 1 | -81.32 | -40.87 | -49.66 | -56.04 | -72.56 | -99.95 | -111.9 | -124.7 |
| EBIT 1 | -81.88 | -41.66 | -50.36 | -56.62 | -72.84 | -98.56 | -113 | -102.6 |
| Net income 1 | -82.18 | -39.22 | -42.49 | -49.38 | -66.49 | -93.27 | -111.7 | -93.5 |
| Net Debt 1 | - | - | - | -126.7 | - | -150 | -133 | -116 |
| Reference price 2 | 3.1700 | 5.0300 | 1.5600 | 1.4500 | 5.3700 | 0.8567 | 0.8567 | 0.8567 |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | 177,862 | 180,088 | - | - |
| Announcement Date | 3/18/22 | 3/15/23 | 3/21/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 20.98x | 31.37x | 12.47x | 0.31% | 43.39B | |
| Weighted average by Cap. | 22.27x | 32.04x | 13.55x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CMPX Stock
- CMPX Stock
- Valuation Compass Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
